moneyheap
MEDP · Analysis updated Nov 10, 2026, 6:00 PM ET
Why is Medpace Holdings, Inc. Common Stock (MEDP) stock moving?
The only news found for the last two weeks is a routine webinar announcement on Nov 2 and the SEC filings for Q3 2026: an 8-K furnishing the Oct 21 results release and a 10-Q filed Oct 22. The text of the results release and the 10-Q was not provided, so revenue, earnings, bookings and guidance cannot be assessed, and that is the main gap in the evidence. The price action shows the stock peaked at 692.68 on Oct 28, fell to a 30-day low of 634.98 on Nov 5, and recovered to 664.54 on Nov 10, which is still below the Oct 28 high. Volume spiked to 894K shares on Oct 22, the day after the results release, against typical daily volume of roughly 200K to 300K, and then faded to 165K on Nov 10, suggesting the post-results interest has cooled. Overall the evidence is thin and mostly neutral, so no strong directional call is supported until the reported figures and management commentary are reviewed.
News behind the analysis
- Medpace Announces Webinar on Glomerular Disease Clinical TrialsMedpace is hosting a webinar on integrated, cross-functional strategies for managing glomerular disease clinical trials. It is a routine corporate event with no financial figures.
- 8-K (results of operations, other events, exhibits)Filed under Item 2.02 to furnish the Oct 21, 2026 press release on results for the three and nine months ended Sep 30, 2026. The press release figures are not included in the filing text provided.
- 10-QQuarterly report filed Oct 22, 2026. Its contents were not included in the data provided, so no figures can be drawn from it.
About Medpace Holdings, Inc. Common Stock
Medpace Holdings is a contract research organization (CRO) based in Cincinnati. Drug and medical-device companies hire it to run their clinical trials, from early Phase I studies through Phase IV. What sets it apart is its focus on small and mid-sized biotech clients and its full-service, science-led approach, with strengths in oncology, cardiology, metabolic disease and the central nervous system.
How it makes money
Medpace earns almost all of its revenue from service contracts to plan and run clinical trials for pharmaceutical, biotech and device sponsors. That work covers project management, regulatory affairs, site monitoring, data management and analysis, drug-safety tracking (pharmacovigilance), lab services, imaging and ECG reading. Revenue is recognized as trials move forward, and a large part of it is reimbursed pass-through costs such as investigator fees. Its future revenue shows up in a contracted backlog of roughly $3.2 billion as of Q3 2026. The company has guided to revenue of about $2.8–2.9 billion for full-year 2026.
What usually moves MEDP
- Biotech funding conditions and R&D budgets
- New business awards, cancellations and book-to-bill ratio
- Backlog growth and how fast it converts to revenue
- Worries about AI disrupting clinical research services
- Share buybacks and margin trends